<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061122</url>
  </required_header>
  <id_info>
    <org_study_id>RNN/206/16IKE</org_study_id>
    <nct_id>NCT04061122</nct_id>
  </id_info>
  <brief_title>The Role of Congenital Mucosal Immune System in the Airways of Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>The Role of Congenital Mucosal Immune System in the Airways of Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the role of congenital mucosal immune system in the
      airways of patients with COPD including the impact of ILCs (Innate lymphoid cells) on
      metabolism of epithelial cells.During the research the following methods will be applied:
      measurement of Volatile Organic Compounds (VOCS), airway epithelial cytology and culture.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ILCs profiles, epithelium metabolism measured by VOCS and microbiome profiling (specific 16S
      rRNA-16S ribosomal RNA gene-targeted qPCR) will by determined in the airways of patients with
      COPD after the exacerbation. Microbiome profiling will be based on next generation sequencing
      (NGS) of the 16S rRNA encoding region.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of nasal ILCs (Innate lymphoid cells) after COPD exacerbation</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The assessment of the nasal mucosa material after COPD exacerbation will include: percentage of ILC1, 2 and 3 cells (immunophenotyping and measurement by flow cytometry)</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COPD Exacerbation</condition>
  <condition>Smoking, Tobacco</condition>
  <arm_group>
    <arm_group_label>EX + / ECTS +</arm_group_label>
    <description>Patients suffering COPD exacerbation in last 7 days; active tobacco smokers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EX - / ECTS +</arm_group_label>
    <description>Patients without COPD exacerbation in last 6 months; active tobacco smokers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EX + / ECTS -</arm_group_label>
    <description>Patients suffering COPD exacerbation in last 7 days; quited tobacco smoking at least 12 months earlier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EX - / ECTS -</arm_group_label>
    <description>Patients without COPD exacerbation in last 6 months; quited tobacco smoking at least 12 months earlier</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>airway epithelial smear test</intervention_name>
    <description>all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture</description>
    <arm_group_label>EX + / ECTS +</arm_group_label>
    <arm_group_label>EX + / ECTS -</arm_group_label>
    <arm_group_label>EX - / ECTS +</arm_group_label>
    <arm_group_label>EX - / ECTS -</arm_group_label>
    <other_name>measurement of VOCs</other_name>
    <other_name>culture</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        EX (COPD exacerbation) TS (tobacco smoking)

        Group: EX + / TS + Patients suffering COPD exacerbation in last 7 days; active tobacco
        smokers

        Group: EX - / TS + Patients without COPD exacerbation in last 6 months; active tobacco
        smokers

        Group: EX + / TS - Patients suffering COPD exacerbation in last 7 days; smoking was stopped
        a minimum of 12 months before the first visit

        Group: EX - / TS - Patients without COPD exacerbation in last 6 months; smoking was stopped
        a minimum of 12 months before the first visit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Exclusion Criteria:

          -  Neoplasm

          -  Diabetes

          -  Astma

          -  acute airway infection in last 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pawe≈Ç Majak</last_name>
    <phone>600621878</phone>
    <email>pmajak@o2.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Majak, MD, PhD</last_name>
      <email>pawel.majak@umed.lodz.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Universtity of Lodz</investigator_affiliation>
    <investigator_full_name>Pawel Majak</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

